Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid for Cardiac Protection in CABG
NCT02807727Phase 3Unknown
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Intralipid 10% in reperfusion injury (IRI). Status: unknown.
02
Drugs
Intralipid 10%
03
Conditions
reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02807727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807727.